Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 39-45

  Matsumoto, Sandra S ^a   Haughey, Heather M ^a   Schmehl, Derek M ^a   Venables, Debra A ^a   Ireland, Chris M ^a   Holden, Joseph A ^b   Barrows, Louis R ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cleavable complex formation; DNA cleavage; Makaluvamine; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MAKALUVAMINE DERIVATIVE; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033033203     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00006     Document Type: Article

References (14)

1. Radisky DC, Radisky ES, Barrows LR, Copp BR, Kramer RA, Ireland CM. Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J Am Chem Soc 1993; 115: 1632-8.
2. Carney JR, Scheuer PJ, Kelly-Borges M. Makaluvamine G, a cytotoxic pigment from an Indonesian sponge Histodermella sp. Tetrahedron 1993; 49: 8483-886.
3. Schmidt EW, Harper MK, Faulkner DJ. Makaluvamines H-M and damirone C from the pohnpeian sponge Zyzzya fuliginosa. J Nat Prod 1995; 58: 1861-7.
4. Venables DA, Concepcion G, Matsumoto S, Barrows LR, Lassota P, Ireland CM. Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa. J Nat Prod 1997; 60 408-10.
5. Barrows LR, Radisky DC, Copp BR, et al. Makaluvamines, marine natural products, arc active anti-cancer agents and DNA topo II inhibitors. Anti-Cancer Drug Des 1993; 8: 333-47.
6. Mizuta R, Taccioli GE, Alt FW. The V(D)J recombination defect in the xrs-6 cell line results from a point mutation in the Ku80 gene. Int Immunol 1996; 8: 1467-71.
7. Singleton BK, Priestley A, Steingrimsdottir H, et al. Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol Cell Biol 1997; 17: 1264-73.
8. Swaffar DS, Ireland CM, Barrows LR. A rapid mechanism-based screen to detect potential anti-cancer agents. Anti-Cancer Drugs 1994; 5: 15-23.
9. Minford J, Pommier Y, Filipski J, et al. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry 1986; 25: 9-16.
10. Holden JA, Rolfson DH, Wittwer CT. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990; 29: 2127-34.
11. Ito H, Fukuda Y, Murata K, Kimura A. Transformation of intact yeast cells treated with alkali cations. J Bacteriol 1983; 153: 163-8.
12. Holden JA, Rolfson DH, Low RL. DNA topoisomerase 1 from human placenta. Biochim Biophys Acta 1990; 1049 303-10.
13. Lynch BL, Guince DG, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Human Pathol 1997; 28: 1180-8.
14. Kokoshka JM, Capson TL, Holden JA, Ireland CM, Barrows LR. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product. Anti-Cancer Drugs 1996; 7: 758-65.